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A commentary on
Mutations in SLC20A2 link familial idio-
pathic basal ganglia calcification with
phosphate homeostasis
by Wang, C., Li, Y., Shi, L., Ren, J., Patti,
M., Wang, T., et al. (2012). Nat. Genet. 44,
254–256. doi: 10.1038/ng.1077
Wang et al. (2012) recently identified seven
novel mutations at the SLC20A2 gene in
families from China, Spain and Brazil,
suggesting that Familial Idiopathic Basal
Ganglia Calcification (IBGC) might be a
phosphate imbalance disorder. Expressing
wild-type human SLC20A2 and the
mutated variants, using transport assays
in Xenopus oocytes, resulted in signifi-
cant impaired Pi transport. On the other
hand, mutants did not have an obvious
effect on the Pi transport activity when
co-expressed with the wild-type PiT2 pro-
tein, encoded by SLC20A2. This suggests
that such mutations have an effect through
haploinsufficiency (Wang et al., 2012).
Additional analysis showed that this
gene is responsible for∼50% of the famil-
ial cases (Hsu et al., 2013; Lemos et al.,
2013). More recently, two French families
with IBGC were reported with mutations
at the platelet derived growth factor recep-
tor B (PDGFRB) gene, opening now a new
venue for the comprehension of this phe-
notype as being caused by different molec-
ular failures in mechanisms of vascular
homeostasis (Nicolas et al., 2013).
Familial or sporadic IBGC, often called
by the misnomer “Fahr’s Disease,” is a
neuropsychiatric disorder with variable
clinical outcome, including parkinsonism,
psychosis, dementia and headaches. The
diagnosis criteria include bilateral calci-
fications, often documented with com-
puterized tomography, in the absence
of hormonal and metabolic imbalances.
Such subjects are often misdiagnosed as
patients with schizophrenia, Parkinson’s
disease, bipolar Disorder, and Alzheimer’s
disease (Manyam, 2005; Lemos et al.,
2011).
Calcifications might also be detected
in cerebellum, thalamus and cortex. The
mode of inheritance of IBGC is mainly
reported in literature as autosomal dom-
inant, sometimes displaying anticipation,
a phenomenon widely described in dis-
eases with similar pattern of inheritance
and first reported in familial IBGC by
Geschwind et al. (1999).
Families affected with IBGC also show
a variable clinical manifestation and a lack
of full penetrance. Recent functional stud-
ies aiming to access the expression profiles
of SLC20A2 at the kidney, have reported
that the expression of this gene is tightly
linked to inorganic phosphate (Pi) con-
centration into the organism. Moreover,
together with SLC20A1, these genes act at
the Pi uptake under different conditions
of pH and dietary Pi (Villa-Bellosta et al.,
2009).
Calcification is an unspecific biochem-
ical process occurring normally even
under physiological conditions, through
phosphate deposition and hydroxyapatite
crystals formation, similar to the mineral
fraction of the bones. However, distur-
bances in this process, which are often
related to phosphate transport alterations
at epithelial cells of blood vessels, lead to
calcification around these tissues, jeopar-
dizing the vessels’ elasticity and leading to
arteriosclerosis as well (Villa-Bellosta and
Sorribas, 2011).
Curiously, Wang et al. (2012) and
other authors also reported subjects with
calcifications but no symptoms. Brain
resilience for such lesions is still the most
compelling challenge for the complete
understanding of the pathological mech-
anisms of IBGC and others autosomal
dominant neuropsychiatric conditions.
Argylean et al. (2009) used neuroimaging
techniques to assess the cerebellumtha-
lamocortical connectivity (CbTC) in
individuals with dystonia and compared
these data with that was yielded by the
analysis of this same circuit in control
individuals and asymptomatic carriers
of mutations for dystonia. Their analysis
showed reduced integrity of cerebellotha-
lamocortical fiber tracts, in both clinically
manifesting and nonmanifesting mutation
carriers. In these subjects, reductions in
cerebellothalamic connectivity were asso-
ciated with increased motor activation
responses, consistent with loss of inhibi-
tion at the cortical level. Nonmanifesting
mutation carriers displayed an additional
area of fiber tract disruption, distally situ-
ated along the thalamocortical segment, in
tandem with a proximal cerebellar outflow
abnormality. In individual gene carriers,
clinical penetrance was determined by
the difference in connectivity measured at
these two sites.
Other approaches to investigate the
lack of full penetrance in genetic traits
have been based on functional studies
using the one-thousand-cells nematode
Caenorhabditis elegans. These analyses
state that this phenomenon may occur
due to mitigating mechanisms involving
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“genetic interaction partners,” that is,
genes involved in common molecular net-
works (Burga et al., 2011).
On this perspective, two molecular
mechanisms have been described: the first
one involves a high expression of homol-
ogous genes, which because of its similar
coding sequence, still bears related func-
tions, enabling them to play the role which
should have been done by the damaged
gene. The other mechanism involves Heat
Shock Proteins, which, by folding proteins
into its biologically active conformation,
ends up attenuating the effects of muta-
tions along the peptidic sequence (Burga
et al., 2011).
The haploinsufficiency effect described
by Wang et al. (2012) when expressing
SLC20A2 mutations in Xenopus oocites
lead us to speculate that in asymptomatic
carriers of those deleterious mutations
must have an altered pattern of expression
of paralog genes. This assumption would
be in accordance with the first mechanism
described by Burga and colleagues (2011).
Functional studies in model organisms
may be able to test this hypothesis.
Previous studies with clinical hetero-
geneity of familial IBGC shows that∼40%
of the patients carrying basal ganglia cal-
cification do not show symptoms. We
reported previously that symptoms were
present in only 28 patients with IBGC,
from a total of 47 subjects with calcifi-
cations detected during a linkage analysis
of 6 families (Oliveira et al., 2003). This
suggests that the brain might have mech-
anisms to handle calcifications and the
first symptoms outcome (resilience), how-
ever, we cannot exclude the possibility that
we are still missing the precocious detec-
tion due to less sensitive clinical findings.
On the other hand, it is well established
that studies measuring the total volume
of calcification shows far more deposits
in symptomatic individuals compared to
asymptomatic subjects (Manyam, 2005).
We suggest considering two levels of
penetrance in IBGC: one for the calci-
fication formations and another for the
clinical manifestation but only a proper
follow-up of asymptomatic subjects with
calcifications will detect the exact timing
of the appearance the first symptoms and
will define the limits of brain resilience to
calcifications. An animal model will most
likely provide this answer.
The concept of brain resilience
is intrinsically associated to IBGC
pathophysiology, since this is the
most probable mechanism underlying
the absence of clinical manifestations
pathogenic SCL20A2 mutation carriers.
This lack of concordance between the
genetic and phenotypic statuses, gives rise
to the probabilistic concept of penetrance
in human genetics, that is, the likelihood
of a given damaging genotype turns out to
develop a clinical entity in its carriers.
As for IBGC, the concept of incomplete
penetrance should be further elaborated,
in order to better categorize phenotipically
the individuals present in a given heredo-
gram. On this perspective, we propose the
term “radiological penetrance.”
Imaging genetics is a promising strat-
egy to integrate genotypic and phenotypic
data and more studies—especially those
focusing brain imaging in asymptomatic
IBGC carriers—are necessary to properly
test such hypotheses.
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